Welcome to our dedicated page for Takeda Pharmaceutical Company news (Ticker: $TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharmaceutical Company stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Takeda Pharmaceutical Company's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Takeda Pharmaceutical Company's position in the market.
Rhea-AI Summary
Takeda's ICLUSIG receives FDA approval as the first targeted treatment for frontline Ph+ Acute Lymphoblastic Leukemia in the U.S., showing superior results in MRD-negative Complete Remission rates compared to imatinib.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
-
Rhea-AI Summary
Takeda announces positive Phase 2 results for mezagitamab in patients with primary immune thrombocytopenia, showing safety, tolerability, and efficacy. Plans for a global Phase 3 trial in fiscal year 2024. Mezagitamab demonstrates promising platelet response rates and potential disease remission in ITP patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
-
News
Rhea-AI Summary
Takeda and Biological E. Limited form a strategic partnership to accelerate the manufacturing of QDENGA, a Dengue Tetravalent Vaccine, in multi-dose vials. The collaboration aims to provide up to 50 million doses per year by BE, supporting Takeda's goal of delivering 100 million doses annually by 2030. Dengue poses a significant global health threat, with increasing incidence rates worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
Rhea-AI Summary
Takeda's EOHILIA Receives FDA Approval for Eosinophilic Esophagitis Treatment, Offering Relief to Patients 11 Years and Older
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
-
Rhea-AI Summary
Takeda announces positive topline results from a Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patients with narcolepsy type 1. The trial demonstrated statistically significant and clinically meaningful improvement in objective and subjective measures of wakefulness compared to placebo at week 8. TAK-861 was found to be generally safe and well-tolerated, with no treatment-related serious adverse events reported. Takeda plans to initiate global Phase 3 trials of TAK-861 in NT1 rapidly in the first half of its fiscal year 2024. The results have no impact on the full-year consolidated reported forecast for the fiscal year ending March 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
-
Rhea-AI Summary
Takeda announces the departure of CFO Costa Saroukos, effective April 1, 2024, with Milano Furuta set to succeed him. Saroukos has played a key role in Takeda's transformation and the successful acquisition of Shire PLC. Furuta, with a strong financial background and global experience, is well-equipped to lead Takeda's finance organization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
Rhea-AI Summary
Takeda announced two new U.S. FDA approvals in FY2023 Q3 for FRUZAQLA and ADZYNMA, enhancing its portfolio. The company reported a revenue growth of +4.6% at AER, flat at CER, and a core operating profit change of -12.7% at CER. Takeda's financial results show a strong momentum in its Growth & Launch Products, offsetting the revenue impact of generic entrants. The company remains on track towards its full-year Management Guidance, reflecting significant generic impact, lower coronavirus vaccines revenue, and investment in R&D and data, digital, and technology to secure long-term competitiveness. Takeda's Chief Financial Officer, Costa Saroukos, emphasized the company's vision to discover and deliver life-transforming treatments and the improvement in their debt profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
-
Rhea-AI Summary
Takeda has received FDA approval for GAMMAGARD LIQUID as an intravenous immunoglobulin therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This milestone follows the recent FDA approval of HYQVIA for maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adults with CIDP. The approval is based on results from a prospective, open-label, single-arm, multicenter clinical study that evaluated the efficacy and safety of GAMMAGARD LIQUID in adults with CIDP who developed a relapse in the randomized, double-blinded, placebo-controlled study evaluating efficacy, safety, and tolerability of HYQVIA in adults with CIDP.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
-
Rhea-AI Summary
Takeda's HYQVIA has been approved by the European Commission for the treatment of chronic inflammatory demyelinating polyneuropathy, offering patients a once-monthly maintenance therapy option. The approval expands Takeda's portfolio of immunoglobulin therapies for patients with neuroimmunological disorders. The approval is based on a Phase 3 trial that showed a significant reduction in CIDP relapse rate with HYQVIA versus placebo, with a favorable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
Rhea-AI Summary
Cognizant (NASDAQ: CTSH) has expanded its agreement with Takeda (NYSE: TAK), a global biopharmaceutical company, to support Takeda's digital transformation strategy. The partnership aims to attract additional technology talent and expand Takeda's Innovation Capability Center operations. Cognizant will help Takeda deliver digital capabilities as a service and modernize its operational model, aiming to accelerate Takeda's digital transformation journey and speed time to market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
Takeda Pharmaceutical Company Limited
NYSE:TAK
TAK Rankings
TAK Stock Data
41.77B
1.55B
0%
2.67%
0.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
Chuo Ku
About TAK
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue.